Credit Suisse analyst V. Divan reiterated an Outperform rating and raised its price target on Adamas Pharmaceuticals (NASDAQ: ADMS) to $37.00 (from $35.00) after raising the probability of success for ADS-5102 to 90% (from 80%) on the back of encouraging topline phase 3 data for their lead internal asset ADS-5102 in levodopainduced dyskinesia (LID) in patients With Parkinson's Disease.

Shares of ADMS surged 83% Wednesday as news broke

For an analyst ratings summary and ratings history on Adamas Pharmaceuticals click here. For more ratings news on Adamas Pharmaceuticals click here.

Shares of Adamas Pharmaceuticals closed at $30.85 yesterday.

Analyst Comments Analyst PT Change FDA Momentum Movers Trader Talk

Adamas Pharma (ADMS) Sees Red-to-Green MoveDecember 24, 2015 11:28 AM Adamas Pharma (ADMS) Ramps Into the CloseDecember 23, 2015 3:38 PM Adamas Pharmaceuticals (ADMS) PT Raised to $38 at Needham & CompanyDecember 23, 2015 2:18 PM Aegis Capital Reaffirms Adamas Pharma (ADMS) at 'Buy'; Dyskinesia Secondary Endpoint Also Seen as KeyDecember 23, 2015 12:04 PM Piper Jaffray Remains Bullish on Adamas Pharmaceuticals (ADMS)December 23, 2015 9:12 AM Adamas Pharma (ADMS) Announces Statistically Significant ADS-5102 Phase 3 EASE LID DataDecember 23, 2015 6:20 AM Adamas Announces Positive Top-Line Phase 3 Results of ADS-5102 for the Treatment of Levodopa-induced Dyskinesia in Patients With Parkinson’s DiseaseDecember 23, 2015 6:00 AM